(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Share your pick for the miniature headphones that you generally suggest! - 2Cyber Monday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- 3Manual for Savvy Home Lighting Framework: Lights up Your Space
- 4Remote Headphones: Upgrade Your Sound Insight
- 5The most effective method to Go Down Abundance through Ages with Disc Rates
- The Delight of Perusing: Book Proposals for Each Class
- The most effective method to Offset Album Rates with Liquidity Needs
- How to watch 'A Charlie Brown Christmas' for less with this Apple TV Black Friday deal
- Forget Doctor Strange. Benedict Cumberbatch’s newest role may be his most haunting.
- Shipping: The Corridors of Trade and the Coming of Another Period
- PA accuses Israel of 'human trafficking' after planeload of Gazans arrives in South Africa
- Florida has quietly become America's execution capital
- Excelling at Cash The board: A Manual for Monetary Essentials
- Figure out What Shift Differentials Mean for Your General Attendant Compensation
